The Union World Conference on Lung Health 2023
)
Oxford Nanopore are sponsoring, exhibiting and presenting at this event.
The Oxford Nanopore Satellite symposium will take place on Friday 17th November at 07:15 - 08:15.
The session, chaired by Justin O'Grady, Senior Director, Translational Applications, will highlight the role of the Oxford Nanopore Technologies Drug-Resistant TB sequencing test in the rapid characterisation of drug resistance profiles directly from decontaminated sputum samples in diverse global settings.
Please check below for full speaker details and register to join the satellite session.
Please visit us at Booth #3330 if you are able to attend the event.
Speakers
)
Kristin Kremer, Team Lead Diagnostics, KNCV Tuberculosis FoundationKristin Kremer is the Team Lead Diagnostics at KNCV Tuberculosis Foundation, coordinator of two projects on genome sequencing, and member of the core group of the Global Laboratory Initiative. Previously, she worked at the National Institute for Public Health and the Environment (RIVM), The Netherlands, and the World Health Organization, Regional Office for Europe, Denmark. She has 23 years’ experience in tuberculosis (mainly molecular epidemiology and new diagnostics), and 7 years’ experience in bacterial serological diagnostics (including serological and cellular assays for Lyme borreliosis and COVID-19). She has over 175 publications and is ranked 53th among the Top Microbiology Scientists in The Netherlands.
)
Tara Ness, Pediatric Infectious Diseases Fellow, Baylor of Medicine/Texas Children’s HospitalTara Ness (MD, MPH) is a Pediatric Infectious Diseases Fellow at Baylor College of Medicine. She is passionate about expanding healthcare access to all individuals, regardless of socioeconomic status or geographic location. She works in both clinical and research settings, promoting pediatric health and advancing our knowledge of infectious diseases with a particular focus on TB and HIV.
Background: Combining rapid molecular tests with tNGS can offer a comprehensive approach to TB diagnosis and DST. The automated BD MAX MDR-TB assay as a first-line diagnostic test able to identify M. tuberculosis complex (MTBC), including rifampicin (RIF) and isoniazid (INH) resistant forms. The leftovers of DNA (~10µl) from used BD MAX MDR-TB assay cartridges could be used for the downstream tNGS to identify resistance mutations to second-line drugs, including new and repurposed drugs which are not currently included in any other molecular assays. Here, we performed an evaluation of such integrative approach using sputum specimens from a high MDR-TB incidence country. Materials: The feasibility of targeted NGS (NanoTB® Oxford Nanopore Technologies) was investigated on undiluted BD MAX DNA eluates of 52 MTBC-positive samples from Tajikistan (smear-, n=32; smear scanty, n=4; smear+, n=11; ++, n=3; +++, n=2). For detection of drug resistance both phenotypic drug susceptibility testing and NanoTB® tNGS were compared. Additionally, for detection of RIF and INH resistance, BD MAX results were compared with tNGS. Results: Among BD MAX MTBC-positive samples (n=52), sensitivity for detection of resistance profiles of individual antibiotics with tNGS were: 80,8% for INH and RIF; 76,9% for PZA, EMB and KAN; 82,7% for LFX, MFX and LZD; 75,0% for ETH, BDQ and CFZ; 78,8% for CM, SM and DLM; 86,5% for AMI. The sensitivity for all 24 target genes was 65,4%. Surprisingly, the failure rate among microscopy-positive samples were 15%, although none of microscopy-negative samples failed. Within the subgroup of smear-positive TB samples (n=20) the sensitivity for all individual antibiotics were 80%. In the same time, within the subgroup of smear-negative TB samples (n=32) the sensitivity were even higher for AMI (90,6%); LFX, MFX and LZD (84,4%); RIF and INH (81,3%). The sensitivity for all other drugs were ranging from 79,1% for CM, SM, DLM, to 75,5% for PZA, EMB, KM and 71,9% for ETH, BDQ, CFZ. Conclusions: The combination of BD MAX MDR-TB assay and tNGS proven to be a feasible and comprehensive approach that provides both rapid and sensitive TB detection together with gDST for the most important TB drugs in only 2 days.
Background: Combining rapid molecular tests with tNGS can offer a comprehensive approach to TB diagnosis and DST. The automated BD MAX MDR-TB assay as a first-line diagnostic test able to identify M. tuberculosis complex (MTBC), including rifampicin (RIF) and isoniazid (INH) resistant forms. The leftovers of DNA (~10µl) from used BD MAX MDR-TB assay cartridges could be used for the downstream tNGS to identify resistance mutations to second-line drugs, including new and repurposed drugs which are not currently included in any other molecular assays. Here, we performed an evaluation of such integrative approach using sputum specimens from a high MDR-TB incidence country. Materials: The feasibility of targeted NGS (NanoTB® Oxford Nanopore Technologies) was investigated on undiluted BD MAX DNA eluates of 52 MTBC-positive samples from Tajikistan (smear-, n=32; smear scanty, n=4; smear+, n=11; ++, n=3; +++, n=2). For detection of drug resistance both phenotypic drug susceptibility testing and NanoTB® tNGS were compared. Additionally, for detection of RIF and INH resistance, BD MAX results were compared with tNGS. Results: Among BD MAX MTBC-positive samples (n=52), sensitivity for detection of resistance profiles of individual antibiotics with tNGS were: 80,8% for INH and RIF; 76,9% for PZA, EMB and KAN; 82,7% for LFX, MFX and LZD; 75,0% for ETH, BDQ and CFZ; 78,8% for CM, SM and DLM; 86,5% for AMI. The sensitivity for all 24 target genes was 65,4%. Surprisingly, the failure rate among microscopy-positive samples were 15%, although none of microscopy-negative samples failed. Within the subgroup of smear-positive TB samples (n=20) the sensitivity for all individual antibiotics were 80%. In the same time, within the subgroup of smear-negative TB samples (n=32) the sensitivity were even higher for AMI (90,6%); LFX, MFX and LZD (84,4%); RIF and INH (81,3%). The sensitivity for all other drugs were ranging from 79,1% for CM, SM, DLM, to 75,5% for PZA, EMB, KM and 71,9% for ETH, BDQ, CFZ. Conclusions: The combination of BD MAX MDR-TB assay and tNGS proven to be a feasible and comprehensive approach that provides both rapid and sensitive TB detection together with gDST for the most important TB drugs in only 2 days.
)
Uladzimir Antonenka, Program Manager, Institute of Microbiology and Laboratory Medicine, WHO Supranational Reference Laboratory for Tuberculosis
